Acetylcholinesterase (AChE) present on the surface of the trematode blood fluke Schistosoma has been implicated in the regulation of glucose scavenging from the host blood. Determination of the molecular structure and functional characteristics of this molecule is a crucial first step in understanding the novel function for AChE and in evaluating the potential of schistosome AChE as a target of new parasite control methods. We have determined the primary structure of acetylcholinesterase from Schistosoma haematobium. Immunolocalization studies confirmed that the enzyme was present on the parasite surface as well as in the muscle. The derived amino acid sequence possesses features common to acetylcholinesterases: the catalytic triad, six cysteines that form three intramolecular disulphide bonds, and aromatic residues lining the catalytic gorge. An unusual feature is that the fully processed native enzyme exists as a glycoinositol phospholipid (GPI)-anchored dimer, but the sequence of the C-terminus does not conform to the current consensus for GPI modification. The enzyme expressed in Xenopus oocytes showed conventional substrate specificity and sensitivity to established inhibitors of AChE, although it is relatively insensitive to the peripheral site inhibitor propidium iodide. Distinctions between host and parasite AChEs will allow the rational design of schistosome-specific drugs and vaccines.
T he best characterized role for acetylcholinesterase (AChE, EC 3.1.1.7) is the regulation of access of the neurotransmitter acetylcholine (ACh) to acetylcholine receptors (AChR) at cholinergic synapses. Other roles for AChE have received little attention despite their widespread distribution both within different tissues of complex organisms and throughout the phylogeny (1, 2) . The evidence for both ACh and AChE in bacteria and plants suggests that cholinergic molecules appeared early on in evolutionary diversification and may have a wide range of, as yet, undiscovered functions. Parasitic worms are proving interesting in this respect. For example, several nematode worms secrete monomeric AChE into the host intestinal lumen, apparently to interfere with expulsion of the parasite from the host (3) . The trematode blood fluke, Schistosoma, has another distinct function for cholinergic molecules, a remarkable "nonclassical" cholinergic system on the parasite surface membranes that regulates glucose uptake from the host (4) (5) (6) (7) (8) (9) .
Acetylcholinesterase is present in schistosomes as GPI-anchored dimers in the neuro-muscular tissues where it is a component of a "classical" cholinergic system and as the same molecular form on the non-excitatory parasite surface (4, 5) . Nicotinic AChRs (nAChR) have also been identified on this surface (6). In vitro exposure of the parasites to ACh alters their rate of glucose uptake, an effect that can be ablated by inhibition of either the surface AChE or nAChRs (7). Glucose is known to be transported by conventional GLUT 1-like transporters in this membrane, so this work reveals a novel method of regulating "conventional" glucose uptake. The function for AChE in this system is assumed to be that of limiting the interaction of ACh with the receptor, because inhibition of AChE results in an effect that mimics ligand excess. In vivo, the ACh is likely derived from the host bloodstream because the optimal effect varies between parasites of humans and cattle according to the respective host's circulating ACh levels (8, 9). Thus this reaction appears to be a conventional one between cholinergic molecules but one that has a unique consequence.
This system and its component molecules are of interest for two principal reasons. Firstly, in the light of this unusual role of AChE, we considered it important to determine the molecular structure and functional characteristics of this molecule as a first step in understanding precisely how AChRs and AChE interact in order to potentiate transmembrane glucose transport. Secondly, Schistosoma is responsible for upwards of 200 million human infections in tropical and subtropical regions. Currently, control of schistosomiasis is largely reliant on a single safe and effective drug, praziquantel, but the introduction of mass treatment programs is providing the first evidence of emerging drug resistance and there is an acknowledged need for novel treatments and prophylactics. There have been considerable advances in vaccine discovery, but there is a continuing search for additional candidate molecules. To date, drug discovery and much of the molecular vaccine discovery have been dependent on empirical approaches largely because of the lack of basic biological knowledge and genomic information.
One rational approach is to identify molecules that are potential targets of both chemotherapeutic and immune control. To qualify, a molecule must be surface located or secreted and of significant or vital function to the survival of the parasite. Our approach has been to discover the mode of action of a known effective drug in order to design improved drugs or to design novel methods of interrupting the identified function. Surprisingly, the primary targets of most effective schistosomicides, including praziquantel, are not known (10) . In the case of metrifonate, an organophosphate drug, schistosome muscle AChE was assumed to be the target but we have since shown that the parasite surface AChE is the more likely. Metrifonate is no longer widely used therapeutically because it distinguishes poorly between host and parasite AChE and is thus toxic. However, because AChE is a known target of an effective drug and has an important function, we consider that surface AChE is a priority target for specifically designed drugs and/or vaccines. Knowledge of the primary structure and functional characterization of the schistosome AChE is an essential requirement.
MATERIALS AND METHODS

Parasites
Adult S. haematobium (Kenyan strain) were obtained from hamsters by portal vein perfusion. cDNA Synthesis -S. haematobium mRNA was purified by using the Oligotex System (Qiagen, Hilden, Germany) from total RNA extracted in phenol-chloroform from frozen ground tissue. The cDNA library was synthesized by using a modification of the SMART system (Clontech, Palo Alto, CA), which selected for full-length cDNAs and introduced unique 5' and 3' flanking sequences to facilitate rapid amplification of cDNA ends (RACE)-type polymerase chain reaction (PCR) without the need to package the cDNA.
Cloning and sequencing
S. haematobium cDNA was screened by PCR by using degenerate primers derived from a total of nine highly conserved sequences within AChEs. Two of these primers, deduced from EMWNPNT (82-88, Torpedo californica numbering) and WIYGGGF (114-120), amplified a product ~140 bp. Sequence analysis indicated this product to be a fragment of a S. haematobium AChE (ShAChE) coding region. Nondegenerate primers derived from this fragment were used in conjunction with primers directed towards the unique cDNA library 5' and 3' flanking sequences in order to obtain the complete coding region by PCR with Pfu DNA polymerase (Stratagene, La Jolla, CA).
Vector Construction and Expression in Xenopus laevis oocytes
We attempted expression of ShAChE in X. laevis oocytes from both cDNA and cRNA. The complete coding region for ShAChE was amplified from the cDNA library by using primers incorporating restriction sites to allow subcloning into either the Not I site of the cDNA expression vector pMT3 (11) or the Bgl II site of the transcription vector pSP64t (12) . Stage IV and V oocytes from adult female X. laevis were defolliculated by treatment with 1 mg/ml collagenase (type 1A; Sigma, St. Louis, MO) in calcium-free Ringer solution (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM N-(2-hydroxyethyl) piperazine-2'-(2-ethanesulphonic acid)
[HEPES], pH 7.5). For cDNA expression, 25 nl (25 ng) miniprep DNA was injected directly into the nucleus, which was visible as a clear area in the oocyte animal pole following centrifugation for 10 min at 400 x g. For cRNA expression, 50 nl (~50 ng) polyadenylated, capped cRNA (synthesized by using the RiboMAX SP6 RNA kit and Ambion Cap; Promega, Madison, WI) was injected intracytoplasmically. Following injection, batches of 20 oocytes were incubated at 19 °C in 1 ml modified Barth's medium (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO 3 , 0.82 mM MgSO 4 .7H 2 O, 0.33 mM Ca(NO 3 ) 2 .4H 2 O, 20 mM HEPES, 0.41 mM CaCl 2 , 1000 units/ml penicillin, 0.1 mg/ml streptomycin, pH 7.5) supplemented with 1 mg/ml bovine serum albumin. Incubation medium was replaced every 24 h and assayed for secreted esterase activity. In order to determine unsecreted activity, we collected batches of 10 oocytes at 24-h intervals and homogenized them in 500 µl Tris-HCl, pH 7.4, containing 1 % Triton X-100. Homogenate was centrifuged three times at 13000 x g for 10 min at 4 °C in order to produce clear oocyte supernatant samples.
Physical characterization
We introduced the coding region for six histidine residues by PCR into the pSP64t ShAChE construct immediately before the termination codon. This step allowed the expression of a C-terminal histidine fusion protein, which was purified from the oocyte incubation medium by affinity chromatography by using Ni-NTA agarose (Qiagen) according to the manufacturer's protocol. The purified enzyme was resolved on a 7.5 % sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel under reducing conditions.
Esterase activity
Acetylcholinesterase activity in incubation medium or cleared cell supernatant was assayed spectrophotometrically according to the procedure of Ellman et al (13) . Briefly, samples were assayed in a total volume of 300 µl containing 40 µl sample, 10 µl medium, 200 µl Ellman's reagent (1 mM dithionitrobenzoic acid, 0.01% gelatin, 0.1 M Tris buffer, pH 7.6) and 50 µl of substrate (either acetylthiocholine iodide (ATCh) or butyrylthiocholine iodide (BuTCh)). Each assay was performed in triplicate at 21 °C, in a 96-well microtiter plate format. Parallel samples in which secreted enzyme was substituted with modified Barth's medium were included in order to correct for spontaneous hydrolysis of substrate. For inhibitor studies, the 10 µl medium was substituted with inhibitor and samples were pre-incubated for 20 min before addition of ATCh. We evaluated inhibition with BW284c51, dichlorvos, and eserine by using a range of inhibitor concentrations and ATCh at a final concentration of 1 mM. We determined K I for the peripheral anionic site inhibitor propidium from comparisons of rates of substrate turnover over a range of substrate concentrations in the presence and absence of inhibitor by using the EnzPack enzyme kinetics analysis software (Biosoft, Cambridge, UK). We monitored reactions by measuring absorbance at 412 nm with a Molecular Devices (Sunnyvale, CA) SPECTRAmax 3240 PC controlled from a PC running SOFTmax PRO software. We took recordings every 15 s beginning from the addition of substrate over 15 min.
Antibody production and immunolocalization
To facilitate the rational design of peptides for immunolocalization, a molecular model of ShAChE was constructed by comparison with the deduced three-dimensional structure of Torpedo AChE (14) by using the first approach protocol of the Swiss-Model automated protein modeling server (Swiss Institute of Bioinformatics, Switzerland). We viewed the predicted model of ShAChE by using the RasMol program (Glaxo Wellcome Research and Development, UK). Short peptides were chosen based on their limited secondary structure in the complete molecule, their presentation on the external surface of the molecule, and their dissimilarity in primary structure to other AChEs (including mouse and human) as inferred by multiple sequence alignments (Fig. 2) . The antibody used for immunolocalization was raised against a 16-residue synthetic peptide LDAHDTMYDPASYFSV (Sigma Genosys), conjugated to cBSA (Pierce, Rockford, IL). This peptide, corresponding to L330-V345, had the advantage of being highly variable, not only across species, but also between esterases within the same species (16) . Polyclonal antibodies, raised in CBA mice to the conjugated peptide, were used to localize ShAChE in 10 µm frozen sections of adult worms or intact live parasites. Worm sections were blocked with 1% fish gelatin in phosphate buffered saline (PBS) (pH 7.4) for 1 h at 4 °C, then washed with PBS. Intact worms were perfused from hamsters by using (RPMI-1640, SigmaAldrich Company Ltd., Dorset, UK) containing heparin and were washed in RPMI. Sections or whole worms were then incubated for 1 h at 4 °C or 20 °C, respectively, in sera diluted to 1/30. Samples were washed three times for 10 min in PBS and then incubated with FITC-labeled donkey anti-mouse immunoglobulin secondary antibody (F(ab) 2 fragments (Jackson ImmunoResearch, West Grove, PA) at 1/50 final dilution for 1 h and then washed. Control antibodies used were from prebleeds of immunized mice and mice immunized with irrelevant antibodies conjugated to cBSA, as well as secondary antibody used alone. Samples were mounted on slides in Cytifluor for viewing by fluorescent confocal microscopy by using a Leica TCS confocal scanning microscope (Leica Ltd., Milton Keynes, UK). The size of the imaging files collected was 512 x 512 pixels.
RESULTS
Sequence determination of ShAChE cDNA
We screened four S. haematobium cDNA libraries representing different adult life stages by PCR by using various combinations of nine degenerate primers deduced from sequences highly conserved in AChEs of vertebrates and invertebrates. Only one PCR product was obtained that could be identified by BLAST analysis (17) as being homologous to previously characterized AChEs. This was a 141 bp product derived from primers corresponding to conserved regions EMWNPNT (82-88) and WIYGGGF (114-120) (numbers in parentheses refer to Torpedo californica AChE). Nondegenerate primers derived from this product were used in conjunction with the unique cDNA library 5' and 3' flanking sequences to isolate the complete reading frame of ShAChE. This cDNA sequence was verified by comparing products amplified by several independent PCR reactions from all four S. haematobium cDNA libraries. We also screened libraries for the presence of alternative C-terminal splice variants of this cDNA by 3'-RACE but found none.
The ShAChE cDNA (GenBank™/EBI Data Bank accession number AF279462) comprises a single open reading frame of 2067 bp, a 5' untranslated region of at least 84 bp, a 123 bp 3' untranslated region, and a poly(A) tail (Fig. 1) . The ShAChE cDNA sequence does not possess the common AATAAA polyadenylation sequence but rather contains an AT-rich region near the 3' end, which includes the ATTAAA motif, a frequent alternative polyadenylation signal (18) (Fig. 1) .
Characteristics of deduced primary structure
The predicted open reading frame encodes a protein of 689 amino acids (Fig. 1) , including a putative signal peptide of 25 residues (19) . An alignment of amino acid sequences (Fig. 2) illustrates the high degree of homology shared by the ShAChE protein with other previously characterized AChEs from both vertebrates and invertebrates. Thus, ShAChE shares 34% identity and 47% similarity with ACE-1 of Caernorhabditis elegans, 29% and 41% with Drosophila melanogaster AChE, 32% and 48% with Torpedo californica, 33% and 44% with Gallus gallus, and 33% and 47% with Homo sapiens. The ShAChE sequence possesses the key features common to AChEs (20) : A catalytic triad consisting of S255 (S200), E384 (E327) and H519 (H440); the active site motif FGESAG surrounding the active serine (underlined); six cysteine residues involved in formation of three intrachain disulphide bonds, C115-C142 (C67-C94), C309-C320 (C254-C265) and C471-C640 (C402-C521); and aspartic acid residues D227 and D466 (D172 and D397), which form salt bridges with R205 and R636 (R149 and R517), respectively. Of the 14 functionally important aromatic residues of Torpedo AChE that line the catalytic gorge, 10 are conserved or conservatively substituted in ShAChE, including W132 (W84), which is known to be essential for substrate binding (14, 21) . There are five putative Nglycosylation sites in ShAChE. Only two N-glycosylation sites are conserved in the majority of AChEs; one corresponding to N457 in Torpedo and another occurring in the region of the second intrachain disulphide bridge. Although in ShAChE the former N-glycosylation site is absent, the latter is present at N298 (R254) (Fig. 2) .
Expression of recombinant ShAChE
Initial attempts to express esterase in Xenopus oocytes by intranuclear injection of cDNA proved unsuccessful. In contrast, oocytes injected intracytoplasmically with cRNA encoding the ShAChE open reading frame expressed functionally active enzyme. Significant levels of activity above the background of endogenous cholinesterase were detected in detergent extracts of whole cell homogenates within 24 h of injection and activity increased steadily to reach a maximum after 120 h (Fig. 3A) . Activity could also be recorded from enzyme secreted into the incubation medium 24 h after injection, reaching a peak after 72 h (Fig. 3B) . No esterase activity was evident in the incubation medium of control oocytes, which were injected with water only. SDS-PAGE performed under reducing conditions revealed that ShAChE purified from the incubation medium appeared as a single band of approximate size 116 kDa (Fig. 3C) . The difference between this value and that predicted for the core polypeptide, which is 80 kDa, probably reflects posttranslational modifications, including glycosylation at one or more of the five putative Nglycosylation sites (Fig. 3) .
Substrate and inhibitor specificities
Hydrolysis of ATCh and BuTCh by secreted ShAChE was evaluated. At a substrate concentration of 1 mM, ShAChE hydrolyzed ATCh five times faster than BuTCh. We observed excess substrate inhibition at ATCh concentrations greater than 10 mM. We obtained K M values of 199 ± 9.8 µM with ATCh and 399 ± 2.5 µM with BuTCh, using substrate concentrations from 0.125 to 8 mM, by using the Direct Linear Plot (mean ± SE, n=3). The higher activity and specificity for ATCh over BuTCh is typical of AChEs.
The effect of cholinesterase inhibitors on recombinant ShAChE activity was also determined. ShAChE was sensitive to the classical AChE inhibitors BW284c51 (82% inhibition after 20 min at 3 µM), eserine (95% inhibition after 20 min at 3 µM), and also to dichlorvos, the active metabolite of the organophosphate schistosomicide metrifonate (90% inhibition after 20 min at 3 µM). ShAChE was not very sensitive to the peripheral site inhibitor propidium iodide (K I = 22 ± 3.7 µM compared with 1.4 µM for recombinant human AChE (22) . No inhibition was detected for the butyrylcholinesterase (BuChE) inhibitor iso-OMPA up to a concentration of 0.1 mM and at 1 mM, less than 20% inhibition was observed.
Immunolocalization
ShAChE was immunolocalized in both intact live worms and unfixed frozen sections by using polyclonal mouse antibodies raised against a region unique to the parasite esterase. Immunofluorescence on worm sections was localized to the worm surface and the muscle tissues located immediately beneath (Fig. 4A) . Confocal microscopy of intact live worms showed clear labeling of the worm surface alone (Fig. 4B) . Control experiments using irrelevant primary antibodies or the detecting antibody alone showed no significant labeling demonstrating that this pattern of immunofluorescence was specific for ShAChE antibodies (Fig. 4) 
DISCUSSION
In this report we describe the nucleotide and derived amino acid sequence of a cDNA encoding S. haematobium AChE (ShAChE) and functional characterization of heterologously expressed protein. Immunolocalization suggests that the cloned ShAChE corresponds to both the muscle and surface enzyme, thus implicating a role for ShAChE in both neuro-muscular and nonneuronal plasma membrane functions. These data are discussed in relation to the structure and properties of AChEs from other organisms, their potential contribution to molecular taxonomy, and parasite control.
Primary Structure of ShAChE
The schistosome is the most primitive organism to date for which we have complete primary sequence data for AChE. Sequence analysis reveals that the ShAChE primary structure is homologous to those of other AChEs and possesses features common to AChEs of diverse species. The catalytic triad is conserved as well as the six-cysteine residues implicated in disulphide bond formation. Of the 14 aromatic amino acids lining the catalytic gorge of Torpedo AChE, 9 are conserved and one is substituted conservatively in ShAChE. In particular, Torpedo W84 is conserved, which has been shown to be critical for the binding of the quaternary ammonium group of acetylcholine in the active site (21) . Residues F(288) and F(290), which are conserved in vertebrates, have been implicated in determining substrate specificity (22) . All invertebrate AChEs characterized so far conserve or conservatively substitute F(290), whereas residues corresponding to F(288) are non-aromatic (15) . ShAChE is the first AChE reported that replaces F(290) with a non-aromatic reside, V345, and is the first invertebrate AChE that conserves F(288).
In Vitro expression in Xenopus oocytes
Heterologous expression confirmed that the ShAChE cDNA encoded functionally active AChE. Recombinant enzyme expressed and secreted from Xenopus oocytes has a molecular weight ~116 kDa. This size is consistent with that of the processed enzyme identified from parasite extracts by immunoprecipitation by using schistosome AChE-specific antibodies (23) . The recombinant enzyme showed typical AChE characteristics by having a marked specificity for ATCh over BuTCh. The enzyme was highly sensitive to BW284c51 and eserine, classical inhibitors of AChEs, and also inhibited by the metrifonate metabolite dichlorvos but was insensitive to the BuChE inhibitor, iso-OMPA.
The peripheral anionic site of ShAChE
The peripheral anionic site (PAS), located near the entrance of the catalytic gorge, has been shown to be involved in excess substrate inhibition. ATCh has modest affinity for the PAS, and binding accelerates hydrolysis at low substrate concentrations but is also responsible for substrate inhibition at high concentrations, likely by steric blockade of substrate dissociation from the active site (24) . Mutagenesis studies on human AChE indicate that substrate binding the PAS triggers a relay of conformational changes involving W(279), D(72), Y(334), F(331), and Y(330) (25) . Differences in this region may account for the relative insensitivity of ShAChE compared with human AChE with respect to substrate inhibition (>10 mM and 1 mM, respectively) and to propidium, a PAS binding inhibitor (24) . In ShAChE, all the PAS residues implicated in substrate interaction are conserved except for W(279), located at the lip of the catalytic gorge. Several residues implicated in substrate interaction also contribute to propidium sensitivity. For example, mutation of W279 to nonaromatic aspartic acid in human AChE decreased affinity to propidium as well as sensitivity to excess substratem, and this substitution is present in ShAChE. Another possible influence is residue F(290), which when mutated in mouse AChE to the nonpolar residue isoleucine, eliminated excess substrate inhibition (26); in ShAChE the corresponding residue is also nonpolar, valine. Finally, Y(70), which is implicated in propidium binding in human AChE (27) , is replaced by P118. Together, these differences may account for the observed insensitivities to propidium and high-substrate concentration.
The ShAChE C-terminus
Vertebrates possess a single AChE gene with enzyme polymorphism arising from alternative splicing of exons encoding the C-terminus (28) . Three distinct C-terminal exons have been characterized, which dictate the final molecular form of the processed enzyme: GPI-anchored dimers are derived from an H (hydrophobic) C-terminal domain; tetrameric forms, which are usually associated with a collagen-like tail or a 20 kDa hydrophobic anchor, are generated from a T (tailed) domain; and secreted, monomeric forms are generated by an S (soluble) domain. In addition, the H and T exons contain a cysteine residue that mediates oligomerization of AChE subunits via disulphide bonds. Invertebrates also possess H, T, and S C-terminal peptides, but here diversity of molecular forms is generated by individual genes as opposed to alternative splicing (20) . In insects, mollusks, and the cephalochordate amphioxus, only AChEs with H peptides are evident (29, 30, 31) , whereas several AChE H genes and an AChE T gene are present in the nematode C. elegans (15) and two cDNAs encoding AChE S forms have been cloned from the parasitic nematode Nippostrongylus brasiliensis (32) .
Sedimentation analysis suggests that only one fully processed molecular form of AChE exists in schistosomes, a globular dimer that is GPI-anchored (5). Our localization studies with unfixed tissues have confirmed that ShAChE is anchored to the outer parasite surface and the underlying muscle. The deduced sequence of the ShAChE C-terminus however does not conform to the characteristics of H peptides elucidated so far (Table 1) , because it does not contain a conventional GPI addition signal consisting of a hydrophilic region of 8-12 amino acids followed by a hydrophobic stretch of 8-20 residues (38) . Instead, the ShAChE C-terminus is truncated and hydrophilic, more like that of S type subunits. However the ShAChE terminus differs from known secreted AChEs in being less hydrophilic and in having the C-terminal cysteine required for dimerization, which is found only in T and H types. Being truncated and devoid of aromatic residues, the ShAChE C-terminus does not conform to the T peptide either. ShAChE therefore possesses an unusual type of C-terminus (Table 1) .
We have addressed the possibility of multiple AChE genes or alternative C-terminal splice variants. Our cloning strategy used all combinations of nine degenerate primers derived from highly conserved AChE sequences, but we have consistently obtained only this single cDNA from a total of four different S. haematobium libraries, as well as libraries from other schistosome species, S. mansoni and S. bovis. Since it is clearly the dominant mRNA produced by the parasite and the only detectable protein in vivo is GPI-anchored (5), we consider it unlikely that there are other genes encoding schistosome AChEs. In addition, we have excluded the possibility of alternative C-terminal splice variants by establishing the position of the final intron in the ShAChE gene (data not shown) and by using anchored 3' RACE to amplify potential alternative final exons. No alternatives were found. Thus despite the unconventional C-terminus, all other evidence suggests that this is the GPI-anchored schistosome AChE. Because Xenopus oocytes do not reliably recognize the primary sequences for GPI-addition, we were not able to screen experimentally for the presence of a GPI anchor in our recombinant ShAChE. We have attempted to produce ShAChE in an alternative eukaryotic system, Pichia pastoris, which does process GPI-anchors appropriately, but the levels of expression we obtained were too low to be characterized.
Distribution of ShAChE
Immunolocalization studies with polyclonal antibodies specific for a unique region of the protein shows that ShAChE is present on the parasite surface, as well as in the underlying musculature. The latter location implicates ShAChE in the conventional role of controlling neuro-muscular activity, but the surface location is of particular interest. Previous studies have implied an important function for the enzyme at this location, because it is rapidly replaced after removal from the surface by enzymatic cleavage at the GPI-anchor by using phosphatidylinositol-specific phospholipase C (39) . More recent work suggests that the surface esterase performs a novel role in regulating glucose scavenging from the host blood (7). Because of its surface location and importance in schistosome nutrition, the AChE may be exploitable as a target for parasite control. Indeed, the surface enzyme is likely the target of an existing schistosomicide, the organophosphate metrifonate (23) . Metrifonate, however, is not specific for schistosome AChE and must be administered sporadically to avoid toxicity to the host (40) . Moreover, schistosome species differ in their sensitivity to doses tolerated by the host (23) . We intend to use information obtained from cloning the schistosome AChE in the development of improved treatments, which are parasite-specific and long lasting.
Potential for drug and vaccine design
Overall, the schistosome and human AChEs share 33% identity and 47% similarity and the active site is conserved. However, other functionally significant regions of these molecules are highly divergent, thus presenting an opportunity for designing discriminating inhibitors.
The primary structure of ShAChE is distinct in several regions implicated in the PAS and the putative back door. As well as being involved in excess substrate binding and interaction with certain inhibitors, the PAS is thought to be the docking point for the substrate before entering the catalytic gorge (20) . Ligand binding studies in Torpedo AChE indicated the involvement of several peptide stretches in the PAS, most notably 251-NLNCNLNSDEELIH-264 and 270-KPQELIDVEWNVL-283. In human AChE, these peptides differ from the ShAChE sequences by 86% and 100%, respectively, with the human enzyme containing a four amino acid insertion in the former.
The putative back door allows the exit of reaction products without interfering with passage of substrate through the catalytic gorge, thus explaining the capacity of this enzyme to hydrolyze substrate at a very high rate (41) . In this proposed mechanism, the movement of residues W(84), V(129), and G(441) causes a channel to open and allow the escape of reaction products. More recently, studies of Electrophorus AChE implicated the peptide (441)-EKRLNYTLEEERLSR-(455) in regulating back door function and that antibodies binding either this region or the PAS are capable of inhibiting enzyme activity (42) . Even though the residues W(84), V(129), and G(441) are conserved in human and schistosome AChEs, the regions surrounding these residues differ considerably. Regions equivalent to the above peptide (441)-(455) differ by 73% between human and schistosome AChEs, and the ShAChE peptide also contains a five amino acid insertion. Currently, we are assessing the ability of antibodies raised against the ShAChE PAS and back door to inhibit enzyme function and thus compromise parasite survival in vivo. Table 1 ShAChE possesses an unusual C-terminal peptide.
Type Peptide C-terminal sequence Molecular form H Torpedo (33) ACDGELSSSGTSSSKGIIFYVLFSILYLIFY Dros. (34) GTCDGDSGSASISPRLQLLGIAALIYICAALRTKRVF GPI-anchored dimer GPI-anchored dimer T Torpedo (35) ETIDEAERQWKTEFHRW-SSYMMHWKNQFDQY--------SRHENCAEL ACE-1 (36) ADVGDPYLVWKQQMDKWQNEYITDWQYHFEQYKRYQTYRQSDSETCGG collagen-tailed amphiphilic tetramer S Bungarus (37) VDPPRADRRRRSARA Nippo. The three types of exons encoding C-terminal domains of cholinesterases are indicated, H (hydrophobic), T (tailed), and S (soluble), each with an example sequence from a vertebrate and invertebrate AChE. Cysteines that may be involved in intersubunit disulphide bond formation are shaded, and conserved aromatic residues in T peptides appear in bold type. Regions removed from the mature proteins are underlined. Dros. indicates Drosophila melanogaster, whereas Nippo.
indicates Nippostrongylus brasiliensis of both B and C forms. Residues of interest are indicated: *residues of the catalytic triad; ^cysteines forming three intrachain disulphide bonds; (shaded) amino acids conserving or conservatively substituting the 14 aromatic residues lining the catalytic gorge of Torpedo AChE; #residues involved in salt bridge formation. Overlined region corresponds to the sequence chosen for the generation of specific antibodies for immunolocalization studies. C-terminal peptides are marked by an arrow, and the GPI addition signal of Torpedo AChE is doubly underlined. The alignment was compiled by using CLUSTALW (15) . 
